WIN Consortium maakt programma WIN Symposium 2012 bekend
Array
WIN Consortium maakt programma WIN Symposium 2012 bekend
Het vierde WIN Symposium over Gepersonaliseerde geneesmiddelen tegen kanker (WIN 2012), dat op 28-29 juni 2012 wordt gehouden in Parijs, Frankrijk, wordt ook dit jaar opnieuw een uniek forum met belangrijke sprekers uit de academische wereld, de industrie en regelgevende instanties uit de hele wereld.
Zij zullen manieren bespreken om de doelmatigheid van kankertherapieen te verbeteren op het niveau van de individuele patient door op de meest effectieve manier gebruik te maken van biomarkers en innovatieve kankertherapieen. Zie http://www.winconsortium.org voor registratie en het indienen van posters.
Engelstalig bericht:
The 4th WIN Symposium in Personalized Cancer Medicine, to be held in Paris, France, June 28-29, 2012 (WIN 2012), will be again this year the unique forum featuring high-ranking speakers from academia, industry and regulatory agencies worldwide. They will address ways to improve the efficacy of cancer therapeutics at the level of the individual patient by using biomarkers and innovative cancer therapeutics in the most effective way.
Registration and call for poster are open on www.winconsortium.org.
The best posters will be awarded.
The WIN 2012 program brings together a unique assembly of top speakers, contributing to the various sessions:
Fundamental concepts and strategies to improve efficacy of therapeutics
- Fabien Calvo, French National Cancer Institute, France
- Ronald DePinho, UT MD Anderson Cancer Center, USA
- James Doroshow, National Cancer Institute, USA
- Edison Liu, Human Genome Organisation HUGO & Jackson Laboratory, USA
- Christopher A. Viehbacher, Sanofi, France
WIN Consortium – Global innovative clinical trials
- Fabrice Andre, Cancer Institute Gustave Roussy, France
- Raanan Berger, Chaim Sheba Medical Center, Israel
- Razelle Kurzrock, UT MD Anderson Cancer Center, USA
- Vladimir Lazar, WIN Consortium & Cancer Institute Gustave Roussy, France
- John Mendelsohn, WIN Consortium & UT MD Anderson Cancer Center, USA
- Mike Pellini, Foundation Medicine, USA
- Sam Raha, Life Technologies, USA
- Jean-Charles Soria, Cancer Institute Gustave Roussy, France
- Josep Tabernero, Hospital Val d’ Hebron, Spain
Biology-driven diagnostics and therapeutics
- Steven Averbuch, Bristol-Myers Squibb, USA
- Rene Bernards, Netherlands Cancer Institute, The Netherlands
- Richard Gaynor, Eli Lilly and Company, USA
- Paolo Paoletti, GlaxoSmithKline Oncology, USA
- Bin Tean Teh, SingHealth Group, Singapore
Combinatorial biomarkers and efficacy of therapeutics
- Waun Ki Hong, UT MD Anderson Cancer Center, USA
- Jeffrey Jackson, Bristol-Myers Squibb, USA
- Laurence Zitvogel, Cancer Institute Gustave Roussy, France
Patient advocacy organizations
- Janelle Hail, National Breast Cancer Foundation, USA
Innovative targets and new drug discoveries
- Nick Botwood, AstraZeneca, UK
- William Dalton, Lee Moffitt Cancer Center, USA
- Elisabeth Mansfield, Food & Drug Administration, USA
- Christian Meisel, Roche, Germany
- Paul Workman, The Institute of Cancer Research, UK
Innovative therapeutics and clinical trials
- Gerald Batist, McGill University & Segal Cancer Center, Canada
- Stephen Friend, Sage Bionetworks, USA
- Razelle Kurzrock, UT MD Anderson Cancer Center, USA
- Patricia LoRusso, Barbara Ann Karmanos Cancer Institute, USA
- Josep Tabernero, Hospital Val d’ Hebron, Spain
System biology and bioinformatics
- Leroy Hood, Institute for Systems Biology, USA
- John Quackenbush, Dana-Farber Cancer Institute, Harvard School of Public Health, USA
- Yosef Yarden, Weizmann Institute of Science, Israel
WIN 2012 synthesis and perspectives
Richard L. Schilsky, WIN Consortium & University of Chicago, USA
The full symposium program is available on the website of WIN Consortium (www.winconsortium.org).
